Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update

As of January 31, 2024, there were 136 active clinical trials for Parkinson’s disease (PD) listed on ClinicalTrials.gov. These trials are testing various drug therapies and are in different stages of research, called phases 1, 2, and 3. Here’s a simplified breakdown: Total Trials: 136 active trials. Previously Reviewed Trials: 101 trials had been reviewed in earlier reports. New Trials: 35 trials were added since the last review in 2023. Phases of Trials: Phase 1: 30% of trials are in this early phase, focusing on safety. Phase 2: 58% of trials are in this middle phase, focusing on effectiveness. Phase 3: 12% of trials are in this late phase, focusing on overall safety and effectiveness. The trials are categorized into two main types: Symptomatic Treatments (ST): These aim to relieve the symptoms of PD, like tremors and movement issues. Disease-Modifying Therapies (DMT): These aim to slow down or stop the progression of PD by targeting its underlying causes. Symptomatic Treatments (ST) Focus: Relieving symptoms like motor (movement) and non-motor issues. Types of Drugs Tested: Both new drugs and existing drugs being repurposed for PD. Examples: Dopamine-related therapies and other neurotransmitter-based treatments. Disease-Modifying Therapies (DMT) Focus: Addressing the root causes of PD, such as reducing harmful proteins in the brain. Trends: Increasing focus on anti-inflammatory treatments and genetic factors. Examples: Treatments targeting proteins like alpha-synuclein, and therapies for inflammation and genetic mutations like GBA. Cell Therapy and Anti-Inflammatory Treatments Cell Therapy: Trials using cells to repair or replace damaged brain tissue. Anti-Inflammatory Treatments: Trials focusing on reducing brain inflammation, a contributing factor in PD. Trial Outcomes and Progress Completed Trials: 24 out of the 139 trials active in early 2023 were completed by early 2024. Most of these were in Phase 1. Ongoing Trials: Many trials are still ongoing, with expected completion dates in 2024. Delays: It’s common for trials to experience delays, averaging about 10 months. Participant Enrollment Total Participants: Over 16,000 participants are targeted for these trials. Phase Distribution: Most participants are needed for Phase 2 and Phase 3 trials, which are more advanced stages of testing. In summary, there is a lot of ongoing research into PD, focusing on both managing symptoms and trying to modify the disease itself. This research includes a variety of new and repurposed drugs, cell therapies, and anti-inflammatory treatments, aiming to improve the lives of those with PD.